SYS-CON MEDIA Authors: Doug Masi, Mat Mathews, PR.com Newswire, David Smith, Tim Crawford

News Feed Item

EndoChoice® Bolsters Leadership Team

Fast Growing MedTech Company Recruits Experienced CFO

ATLANTA, Aug. 28, 2014 /PRNewswire/ -- EndoChoice® today announced David Gill has joined the company as Chief Financial Officer. The company also announced it has been recognized for the fifth consecutive year as one of the fastest growing companies in the U.S. by Inc. Magazine.

The continued rapid growth at EndoChoice has been fueled by the success of the company's wide range of products and services purposefully designed and built for gastroenterologists. "We are in business to serve the gastroenterology caregiver and this unprecedented growth is recognition that our efforts are appreciated," said Mark Gilreath, Founder and CEO of EndoChoice. "As a result of our expansion and plans for the future, it became important to have a CFO of David's tenure and experience to guide us through our next growth opportunities," Gilreath added.

David Gill has been the CFO of four public companies and led the IPO's of Interland, CTI and NxStage. He joins the company as sales of the new Fuse® Full Spectrum Endoscopy® system have accelerated. "Although colonoscopy is considered the best tool to fight colon cancer, numerous clinical studies have shown this disease continues to plague populations around the world because not everyone is routinely screened and traditional endoscopes miss up to 40% of pre-cancerous polyps. I am excited to join the EndoChoice team and be part of the revolution Fuse is bringing to gastroenterology care," said Gill.

Endoscopes are thin flexible tubes with imaging capabilities that doctors use to view the upper and lower GI tracts of their patients. The Fuse system uses three small cameras at the tip of a flexible GI endoscope, as compared with one at the tip of a standard, forward-viewing endoscope.  With a wider 330 degree view, physicians using Fuse see nearly twice the surface area and anatomy, including behind and into folds where colon cancer causing polyps often hide. A recent clinical study found that Fuse detected 69% more pre-cancerous polyps versus the standard colonoscope. As a result, informed patients are beginning to 'insist on Fuse' for their next colonoscopy.

About EndoChoice
Based in Atlanta GA, EndoChoice® is a medtech company focused on the manufacturing and commercialization of platform technologies including devices, diagnostics, infection control and endoscopic imaging for specialists treating a wide range of gastrointestinal diseases. EndoChoice leverages its direct sales organization to serve more than 2,000 customers in the United States and works with 34 distribution partners world-wide.  The Company was founded in 2008 and has rapidly developed a proprietary product portfolio, which includes the revolutionary Full Spectrum Endoscopy® System (Fuse®). 2014 marked the fifth consecutive year EndoChoice was recognized as one of the fastest growing companies in the U.S. by Inc. Magazine. To learn more, visit www.endochoice.com

EndoChoice® and Fuse® are registered trademarks of EndoChoice, Inc.

For more information, press only:

Doug Ladd, Chief Marketing Officer
513-608-6873 or [email protected]

For more information on Fuse®

www.endochoice.com/fuseor www.fusecolonoscopy.org

 

SOURCE EndoChoice

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.